IP Library Granted Patent US 7,807,794
Granted Patent B2
US 7,807,794 · App. 11/601,595 · Granted Oct 5, 2010

Anti-α2 integrin antibodies and their uses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,807,794
App. No.
11/601,595
Granted
Oct 5, 2010
Kind
B2
Abstract

The invention relates to anti-α2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of α2 integrin and inhibit the interaction of α2β1 integrin with collagen. Also disclosed are therapeutic uses of anti-α2 integrin antibodies in treating α2β1-mediated disorders, including anti-α2 integrin antibodies that bind to α2 integrin without activating platelets.

Claims (16)

1. A humanized anti-α2 integrin antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:109.

2. A humanized anti-α2 integrin antibody comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 91.

3. A humanized anti-α2 integrin antibody comprising (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:109; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO:91.

4. The humanized anti-α2 integrin antibody of any one of claim 1 , 2 or 3 , wherein the antibody comprises a constant region.

5. The humanized anti-α2 integrin antibody of claim 4 , wherein the constant region is γ1.

6. The humanized anti-α2 integrin antibody of claim 4 , wherein the constant region is γ4.

7. The humanized anti-α2 integrin antibody of any one of claims 1 , 2 or 3 , wherein the antibody recognizes the I domain of human α2 integrin.

8. The humanized anti-α2 integrin antibody of any one of 1 , 2 or 3 , wherein the antibody binds α2β1 integrin.

9. The humanized anti-α2 integrin antibody of any one of claims 1 , 2 or 3 , which is a full length antibody.

10. The humanized anti-α2 integrin antibody of any one of claims 1 , 2 or 3 , which is an antigen-binding fragment.

11. The humanized anti-α2 integrin antibody of any one of claims 1 , 2 or 3 , bound to a detectable label.

12. The humanized anti-α2 integrin antibody of any one of claims 1 , 2 or 3 , immobilized on solid phase.

13. The humanized anti-α2 integrin antibody of any one of claims 1 , 2 or 3 , wherein the antibody inhibits binding of α2 or α2β1 integrin to an α2β1 integrin ligand.

14. The humanized anti-α2 integrin antibody of claim 13 , wherein the α2β1 integrin ligand is selected from collagen, laminin, Echovirus-1, decorin, E-cadherin, matrix metalloproteinase I (MMP-I), endorepellin, collectin and C1q complement protein.

15. A kit comprising the humanized anti-α2 integrin antibody of any one of claims 1 , 2 or 3 and instructions for its use to detect α2 or α2β1 integrin protein.

16. A composition comprising the humanized anti-α2 integrin antibody of any one of claims 1 , 2 or 3 and a pharmaceutically acceptable carrier.

Assignments (4)
CHANGE OF NAME Recorded Jan 31, 2020
From: GLENMARK PHARMACEUTICALS S.A.
To: ICHNOS SCIENCES SA
Reel/Frame 052159/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2008
From: CHROMOS MOLECULAR SYSTEMS INC.
To: GLENMARK PHARMACEUTICALS S.A.
Reel/Frame 020842/0128 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2007
From: CHROMOS MOLECULAR SYSTEMS INC.
To: GLENMARK PHARMACEUTICALS S.A.
Reel/Frame 019729/0335 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2007
From: LAZARIDES, ELIAS; WOODS, CATHERINE MARY; BERNARD, MARK
To: CHROMOS MOLECULAR SYSTEMS INC.
Reel/Frame 018881/0601 →